Mineralocorticoid receptor antagonist vs. placebo in a patient with end-stage kidney disease under renal replacement therapy: a systematic review and meta-analysis
{{output}}
The number of patients living with chronic kidney diseases is increasing, and so are the patients with end-stage renal disease (ESRD) undergoing renal replacement therapy (RRT). While there is a common understanding that these patients face higher risks of fat... ...
